CTRI/2020/11/029289招募中2 期
A prospective non randomized single arm, single center clinical study to evaluate the effectiveness of Siddha medicine M V Kashayam in the management and treatment of COVID 19 patients
Arul Anandar College0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria
- •1. Patients with positive RT- PCR test
- •2. The age group of 15 yrs to 60 yrs.
- •3. Patients with mild and moderate symptoms of COVID 19.
- •4. Patients of both sex and willing to accept the treatment method.
- •Withdrawal Criteria
- •i) Intolerance to the drug and development of any serious adverse effect during a drug trial.
- •ii) Poor patient compliance & defaulters
- •iii) Patient is unwilling to continue the course of clinical Study.
- •iv) The occurrence of any other systemic illness.
排除标准
- •i.RT- PCR negative patients
- •ii.Patients of less than 15 yrs and above 60 yrs of age.
- •iii.Pregnant and breastfeeding women.
- •iv.Patients with severe COVID 19 symptoms.
- •v.Allopathic Antiviral treatment patients.
研究者
相似试验
尚未招募
2 期
Safety and Effectiveness of Siddha Sastric Medicines for the Management of Covid-19CTRI/2020/07/026470Almaa Siddha Multispeciality Hospital Pvt Ltd
尚未招募
2 期
A Clinical trial on Komoothira Silasathu Chooranam in the management of Thandagavatham (Lumbar spondylosis) among patients attending OPD and IPD of Government Siddha Medical College and Hospital,PalayamkottaiCTRI/2024/06/068547GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITA
尚未招募
2 期
A clinical trail on parangisakkai chooranam in the management of soothagavaayu(PCOD)CTRI/2024/06/069031Government Siddha Medical College and Hospital
尚未招募
2 期
Cervical spondylosis - An oral administration of classical siddha drug Kanduparangi chooranamCTRI/2024/06/068763Government Siddha Medical College and Hospital
已完成
2 期
TROG 99.02 Concurent radiation and chemotherapy for the organ conserving treatment of early anal canal canceranal canal cancerCancer - Bowel - AnalACTRN12610000188033Trans-Tasman Radiation Oncology Group Inc (TROG)58